We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mexico has recently issued a law banning the advertising of 81 dubious so-called
"miracle products," as hopes grow for a crackdown on bogus drugs in
the country.
The UK's Department of Health has outlined a new long-term strategy
for generic drugs dispensed in England by state-run health provider the National
Health Service (NHS).
China's State Food and Drug Agency (SFDA) has issued new regulations obliging
healthcare institutions to obtain registration for their medicinal products.
Bausch & Lomb, the global eye health company, has entered into a definitive
agreement to acquire a 55-percent controlling interest in the Shandong Chia
Tai Freda Pharmaceutical Group (CTF), the leading ophthalmic pharmaceutical
company in China, from Sino Biopharmaceutical Ltd. (HKSE:1177.HK).
Amending the decree, which came into force in 1984 to determine pharmaceutical
purchase on a "cost" basis, the government showed an annual saving
of $750 million.
Key Organics of Cornwall UK has been selected as the latest strategic partner
to work with Prolysis and Proteom in the optimization of Prolysis' lead antibiotic
programmes.
Calpis has entered agreements with Unilever (Unilever PLC and Unilever N.V.)
to license the technologies, patents and trademark and to provide the blood
pressure regulating ingredient AmealPeptide for blood pressure controlling foods
to be manufactured and sold by Unilever in Europe.
Chronogen (Montreal, Canada), a drug discovery company developing novel therapeutics
to treat age-related diseases and Inpharzam Ricerche (Taverne, Switzerland),
subsidiary of the international chemicals and pharmaceutical company, Zambon
Group S.p.A, jointly announced today that they have entered into an R&D
collaboration agreement with the aim of identifying small molecules for the
treatment of cardiovascular and metabolic diseases induced by oxidative damage
and/or lipids disorders.
Despite the recent criticism of changes to Israel's data exclusivity and patent
laws, which have aroused international condemnation, the country continues to
lobby hard for the return of multinationals to the local R&D industry.